



Claims:

We claim:

1. Compound (III)



- 5 which is the monohydrate of the monochloride of compound (I)



2. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2θ value ± 0.2°: 9.3, 10.6, and 13.3.
- 10 3. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2θ value ± 0.2°: 9.3, 10.6, 13.3, 20.7, and 23.3.
4. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the

following reflections, quoted as 2θ value $\pm 0.2^\circ$: 9.3 , 10.6 , 11.4 , 13.3 , 20.7, 23.3 , and 26.0.

5 5. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2θ value $\pm 0.2^\circ$: 6.8, 9.3, 10.6, 11.4, 13.3, 20.7, 23.3, 24.6, 26.0, and 27.6.

6. A pharmaceutical composition comprising ~~pseudopolymorphic form (III)~~ of the compound of ~~formula (I)~~claim 1 and optionally further pharmaceutically acceptable excipients.

10 7. The pharmaceutical composition of claim 6 comprising crystalline form (III) of the compound of the formula (I) mainly and no significant fractions of another form of the compound of the formula (I) and optionally further pharmaceutically acceptable excipients.

8. A crystalline form of the compound of any of claims 1 to 5 for use in the treatment and/or prophylaxis of cancer.

15 9. A pharmaceutical composition of any of claims 6 to 7 for use in the treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases.

10. Use of a compound as defined in any of claims 1 to 5 for the manufacture of a pharmaceutical composition for the treatment or prevention of proliferative disorders, such as cancer and tumor diseases.


20 11. Use of a compound as defined in any of claims 1 to 5 for the manufacture of a tablet which is physically and chemically stable.

~~12. A method of treating or preventing proliferative disorders, such as cancer and tumor diseases in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of the compound as defined in any of claims 1 to 5.~~

25 ~~13.~~12. A process for producing the ~~crystalline form (III) of the compound of claim 1~~formula (I) comprising the step of allowing the compound of formula (I) to react, by dissolution or suspension of the compound of formula (I) in an inert solvent and addition of an acid or acid precursor.


30 ~~14.~~13. The process of claim ~~12~~13, wherein the compound of formula (I) is allowed to react by dissolution or suspension of the compound of formula (I) in THF or EtOH and water, and addition of HCl.

15-14. The process of claim 1314, wherein the compound of formula (I) is produced by allowing a compound of formula (VII)




(VII)

to react in the presence of THF and water with K_2CO_3 and a palladium catalyst with a compound of formula (VIII)




(VIII).

16-15. The process of claim 1415, wherein the compound of formula (VII) is produced by allowing a compound of formula (V) to react




(V)

with a compound of formula (XIII)



(XIII)

with paraformaldehyde in the presence of an acid, to thereby producing a compound of formula (VI),




(VI)

5

and then allowing the compound of formula (VI) to react with a bromination agent.


17-16. The process of claim 1615, wherein the compound of formula (V) is produced by allowing a compound of formula (IV) to react



(IV)


10

with an acid thereby producing a compound of formula (XXII),



(XXII)


and then allowing (XXII) to react with methanol in the presence of a base, thereby producing a compound of formula (XXIII),



(XXIII)


and then allowing (XXIII) to react with formamidine acetate and a base.

18-17. The process of claim 17, wherein the compound of formula (IV) is produced by allowing a compound of formula (X)




(X)

to react with Boc-NH-NH₂ to form a compound of formula (XI)




(XI)

which is allowed to react with ClSO₂NCO to form a compound of formula (XII)



(XII)

which is, in turn, allowed to react with N-bromosuccinimide to form a compound of formula (IX)



(IX)

which is allowed to react with metal organic reagents, preferably with methyl magnesium bromide and butyl lithium, in addition to paraformaldehyde to form a compound of formula (IV).